China Innovation Takes Another Step: Merck KGAA Ties Up With BeiGene On Global Agreement For BRAF Inhibitor
This article was originally published in The Pink Sheet Daily
In a win for China’s innovation strategy, leading local player BeiGene partners its second-generation BRAF inhibitor, which may have opportunities beyond metastatic melanoma where Roche has made its mark with BRAF inhibitor Zelboraf.
You may also be interested in...
Glaxo’s BRAF inhibitor dabrafenib and MEK inhibitor trametinib were approved as single agents for advanced melanoma, but the real promise lies in combination therapy for better efficacy and safety. Labeling for trametinib notes it is not indicated in patients who have already received BRAF therapy.
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.
Merck Serono Opens Bioanalysis Center In Beijing To Support Clinical Trials In Asia; Plans To Double Staff
SHANGHAI - Merck KGaA's biopharmaceutical arm Merck Serono SA opened Aug. 31 a new R&D laboratory in Beijing to establish bioanalysis capability that will support clinical trials in Asia. The site is on Chinese contract research organization Pharmaron's new campus in the Beijing Economic and Technological Development Area